Tissue-type Plasminogen Activator (tPA) is a serine protease produced by endothelial cells. They target plasminogen, an inactive precursor of plasmin and convert the plasminogen into active plasmin, which degrades the fibrin component of thrombus to aid in dissolution of blood clots. Hence tPA is commonly used in treatment of acute Ischemic stroke in the form of recombinant tissue plasminogen activator (rtPA). rtPA is produced using recombinant technology from different types of vectors depending on the quantities required for the treatment of different diseases. Alteplase (intravenous rtPA) is the most common therapy drug used to treat ischemic strokes. This review gives an outline of the in vitro synthesis of rtPA and its usage in treatment of Acute Ischemic stroke.
Ischemic Stroke: The Global and Indian Scenario
The WHO defines stroke as the rapid development of clinical signs and symptoms of a focal neurological disturbance lasting more than 24 hours or leading to death with no apparent cause other than vascular origin [2] . Ischemic strokes are caused cerebral thrombosis or embolism which is caused by hardening of arteries. In the case of thrombic stroke, a clot may form in an artery that is already very narrow while embolic stroke is caused by a clot that breaks off from another place in the blood vessels of the brain, or from some other part of the body, and travel up to the brain. Ischemic stroke can be majorly classified into the subtypes: lacunar, nonlacunar and cardioembolic.
Study estimates state that approximately 20 million people suffer from stroke out of which only 15 million survive [3] . Due to the fact that developed countries have effective screening, evaluation and therapies for stroke against the developing countries have led to high death rates in developing countries due to stroke. This fact can be proved by data which suggest that 85% of global deaths due to stroke are from developing countries [4] . Another shocking fact is that 50% -85% of all strokes come under Ischemic strokes [5] . There is very minimal documented data available on the prevalence and mortality rate associated to stroke in India. However, even the minimal data throws up alarming figures that need to be addressed immediately. The Indian National Commission on Macro-economics and Health estimates an increase in number of stroke cases in India from 1,081,480 in 2000 to 1,667,372 in 2015 with 12% of cases occurring in people below 40 years of age [6] . Hence, these issues need to be addressed quickly.
As per the factsheets of South Asia Network for Chronic Disease, India currently has programs like WHO STEPS programme, INTERSTROKE, INSPIRE, PURE and National programme on prevention and control of cardiovascular diseases, diabetes and stroke, to address issues related to stroke in India [7] . Despite there being so many programs launched with the intend to curb deaths related to stroke, the prospects still remain bleak with an urgent need for the Government of India to step in and takes initiatives which show an intend to facilitate prevention, treatment and rehabilitation to decrease stroke related fatalities in India
The classic symptoms associated with stroke are acute inset of unilateral paralysis, speech impairment, gradual vision and memory loss with the person going into a coma and ultimately death. Quick thinking and therapy is required to save a person who has suffered an Ischemic stroke.
Tissue Plasminogen Activator
The Tissue Plasminogen Activator (tPA) is a 70 kDa serine protease which has 527 amino acid residues that can double as a thrombolytic agent which can be used to dissolve blood clots effectively. Its expression is high in those regions which are in close contact to fibrin clots. Though tPA and urokinase type Plasminogen activator (uPA) are classified as Plasminogen Activators, tPA has more enhanced binding of fibrin to specific regulatory domains than uPA [8] [9] . The fibrin-tPA complex in turn has a high affinity for Plasminogen. Besides, tPA is also the more dominant form produced by cultured human endothelial cells [10] - [14] . The tPA molecule consists of four domains which are functionally different. These include an amino-terminal region called the finger domain, an epidermal growth factor (EGF-like) domain, two kringle domains which are the K1 domain and the K2 domain, and a serine protease region with the active-site residues. The K2 domain is mainly responsible for the high affinity of tPA for fibrin and its activation by fibrin, although finger and EGF domains also contribute to a certain extent to the affinity [15] [16] .
The inactive enzyme precursor plasminogen undergoes proteolytic cleavage to form a two-chain structure plasmin, this cleavage is performed by the tPA with plasminogen binding to tPA and fibrin with high affinity. The receptors of Plasminogen are expressed and found on surface of the endothelial cells. The two main candidate plasminogen receptors are alpha-enolase and annexin-II which interact with plasminogen which in turn gets converted into plasmin. Plasmin has been found to have excellent enzymatic activity on the cell surface and it acts in two ways: by either directly catalyzes the breakdown of fibrin [17] molecules thereby dissolving the blood clot, or by indirectly acting on fibrin by the plasmin-dependent activation of few matrix-degrading proteases like pro-stromelysin and pro-collagenase [18] [19].
Using rtPA in Ischemic Stroke Treatment
The recommended diagnosis for stroke as per the American Heart Association are Electro Cardio Gram, chest X-ray, complete blood count, platelet count, brain imaging, prothrombin and partial thromboplastin time, glucose levels and serum electrolytes.
Comparing to ECG and chest X-ray, the recombinant tissue plasminogen activators (r-tPAs) is FDA-approved for treatment of myocardial infarction with ST-elevation (STEMI) and acute ischemic stroke (AIS). RtPAS used for immediate treatment whereas ECG and other methods only used for diagnosis of stroke. rtPA has become widely considered standard of care in acute ischemic stroke, so long as the patient presents soon after the onset of stroke symptoms.
Hypertension has been proved to be the most powerful predictor for ischemic stroke while diabetes, age beyond 40 years and current smoking are also important indicators [20] . Hyperhomocysteinemia is another cause for ischemic stroke in both young and old people [21] [22] .
Alteplase (intravenous rtPA) is the only thrombolytic agent approved by the US Food and Drug Administration as of date [23] . There are however newer agents like alteplase, pro-urokinase, reteplase, tenecteplase, desmoteplase that are being considered as alternate options though they are not approved for administration so, as of now the best treatment is to use alteplase [24] . The use of tissue plasminogen activator to treat Ischemic stroke is however a highly controversial subject with arguments that the use of the protein is a good solution for the problem as well as arguments that it can cause adverse effects if used for treatment. tPA, certain neurologists believe that its use has risks and lack of efficacy [25] .
Though there are reports which suggest that tPA therapy increased the instances of development of intracerebral hemorrhages from 0.6% in placebo-treated patients to 6.4% in tPA-treated patients [26] . However these numbers are not as grave as it seems because these numbers are still negligible when compared to the number of lives saved and the numbers are also dependant on a number of cases where the rtPA was not administered in time as well as medical errors [27] . Thus the use of recombinant Tissue Plasminogen Activator is justified, arguably the best therapy and is safe to treat Ischemic stroke cases.
In Vitro Synthesis of rtPA: An Overview of Available Methods
The need for use of tissue plasminogen activator as a thrombolytic agent is quite large and hence there is a need to synthesize it in large quantities with good yield, efficiency, proper folding, ease of production sans any type of contamination and high purity. tPA was initially synthesised for therapeutic purposes using Bowes melanoma cells but the need for a reliable process and higher yield led to development of prokaryotic and eukaryotic cell to yield the recombinant tPA [28] . Escherichia coli due to its low production cost has been a favoured choice of organism for researchers all over [29] [30] . The first time human tPA was isolated was from E coli as a single chain serine protease consisting of 527 amino acids and Ser at the N-terminus [31] . But over the years it has been found that human tPA is most difficult to produce in E. coli due to complex challenges posed in obtaining a properly folded structure which has more than two disulfide bonds (17 disulfide bonds) [32] .
A virus expression vector which affects insect cells like Baculovirus expression vector was chosen to produce active rtPA in insect cells. The expression however replicated only in alkaline conditions and hence does not replicate in human cells due to their acidic nature and had lesser glycosylation than the tPA produced in humans [33] . Saccharomyces cerevisiae was another candidate that was chosen for rtPA production. The yeast cells also showed problems with glycosylation and folding. Hence, it was also considered a poor option [34] .
Chinese Hamster Ovary (CHO) cells are the preferred choice for production of rtPA in vitro. Tissue plasminogen activator (rtPA, Activase), in 1987 was the first recombinant therapeutic protein synthesised in CHO-a mammalian cell [35] . Though, a good produce is got from mammalian cells, their drawbacks include high cost of medium, high chances of contamination and high cost of purifying the product. These negative aspects of mammalian cells have led to scientists looking for alternative methods like using members from the Trypanosomatidae family of protozoans to produce rtPA and various other recombinant proteins [36] . However, it remains to be seen if they are effective and economically feasible for commercial production. The future prospective of in vitro synthesized rtPA would be in some cases of diseases that feature blood clots, such as pulmonary embolism, myocardial infarction, and stroke, in a medical treatment called thrombolysis.
Conclusion
Ischemic stroke is caused by accumulation of fat along artery walls in a blood vessel which connects to a part of the brain, formation of a blood clot which blocks a blood vessel. Tissue Plasminogen Activator is an important protein in the human body and plays a significant role in the dissolution of blood clot; this is helpful in treatment of Ischemic Stroke when it is administered within three hours before symptoms of the condition. The large scale production of tPA the protein is tedious and expensive, hence rtPA is synthesized in vitro by several techniques. Till date rtPA remains the most preferred drug for the treatment of Ischemic Stroke though it has numerous side effects associated with it like hemorrhage. Though there are certain controversies existing regarding use of rtPA, studies have comprehensively proved that the use of rtPA is safe and efficient. Hence, it can be suggested that using intravenous rtPA (Alteplase) is at present the most efficient therapy for Ischemic Stroke as the fears of adverse effects said to be caused are unfounded. Ischemic Strokes causes millions of deaths worldwide with India also accounting for a major share of the fatalities. Though there are many initiatives taken to prevent stroke related deaths in India, the prospect is not bright. Hence, it is imperative that newer and effective initiatives are taken by the Government of India to address the issue of stroke and its effective treatment to prevent deaths. This review is concluded with a hope that newer, lesser toxic and more efficient rtPA based thrombolytic agents are developed in the very near future and that they will be used to save many human lives.
